Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma

Journal of Clinical Oncology

Volumn 29, Issue 9, 2011, Pages 1210-1215

  Beasley, Georgia M ^a   Riboh, Jonathan C ^a   Augustine, Christina K ^a   Zager, Jonathan S ^a   Hochwald, Steven N ^a   Grobmyer, Stephen R ^a   Peterson, Bercedis ^a   Royal, Richard ^a   Ross, Merrick I ^a   Tyler, Douglas S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADH1; ANTINEOPLASTIC AGENT; CREATINE KINASE; MELPHALAN; NERVE CELL ADHESION MOLECULE; PENTAPEPTIDE; UNCLASSIFIED DRUG;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTERY INJURY; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DISEASE DURATION; DRUG POTENTIATION; ERYTHEMA; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LIMB PAIN; LIMB TUMOR; LUNG INFILTRATE; MALE; MELANOMA; MULTICENTER STUDY; NEUTROPENIA; NUCLEOTIDE SEQUENCE; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RASH; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CADHERINS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DRUG THERAPY, COMBINATION; EXTREMITIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79952781372     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.1224     Document Type: Article

References (40)

1. Balch CM, Houghton AN, Peters LJ: Cutaneous melanoma, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 4). Philadelphia, PA, JB Lippincott, 1993, pp 1612-1661
2. Pawlik TM, Ross MI, Johnson MM, et al: Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 12:587-596, 2005 (Pubitemid 41126088)
3. Cascinelli N, Bufalino R, Marolda R, et al: Regional non-nodal metastases of cutaneous melanoma. Eur J Surg Oncol 12:175-180, 1986 (Pubitemid 16011038)
4. Calabro A, Singletary SE, Balch CM: Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 124:1051-1055, 1989 (Pubitemid 19231243)
5. Zogakis TG, Bartlett DL, Libutti SK, et al: Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol 8:771-778, 2001 (Pubitemid 34003325)
6. Sun W, Schuchter LM: Metastatic melanoma. Curr Treat Options Oncol 2:193-202, 2001
7. Hochster H, Strawderman MH, Harris JE, et al: Conventional dose melphalan is inactive in metastatic melanoma: Results of an Eastern Cooperative Oncology Group Study (E1687). Anticancer Drugs 10:245-248, 1999 (Pubitemid 29141312)
8. Skene AI, Bulman AS, Williams TR, et al: Hyperthermic isolated limb perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 77:765-767, 1990 (Pubitemid 20236115)
9. Grünhagen DJ, de Wilt JH, van Geel AN, et al: Isolated limb perfusion for melanoma patients: A review of its indications and the role of tumour necrosis factoralpha. Eur J Surg Oncol 32:371-380, 2006 (Pubitemid 44287670)
10. Vrouenraets BC, Nieweg OE, Kroon BB: Thirtyfive years of isolated limb perfusion for melanoma: Indications and results. Br J Surg 83:1319-1328, 1996 (Pubitemid 26342147)
11. Cornett WR, McCall LM, Petersen RP, et al: Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 24:4196-4201, 2006 (Pubitemid 46622299)
12. Taber SW, Polk HC Jr: Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Ann Surg Oncol 4:440-445, 1997 (Pubitemid 127725521)
13. Thompson JF, Kam PC, Waugh RC, et al: Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Semin Surg Oncol 14:238-247, 1998 (Pubitemid 28146516)
14. Thompson JF, Waugh RC, Saw RP, et al: Isolated limb infusion with melphalan for recurrent limb melanoma: A simple alternative to isolated limb perfusion. Reg Cancer Treat 7:188-192, 1994
15. Lindnér P, Doubrovsky A, Kam PC, et al: Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 9:127-136, 2002 (Pubitemid 34259697)
16. Beasley GM, Petersen RP, Yoo J, et al: Isolated limb infusion for in-transit malignant melanoma of the extremity: A well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 15:2195-2205, 2008
17. Beasley GM, Caudle A, Petersen RP, et al: A multi-institutional experience of isolated limb infusion: Defining response and toxicity in the US. J Am Coll Surg 208:706-715, 2009; discussion 715-717
18. Flaherty KT: Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res 12:2366s-2370s, 2006 (suppl 7)
19. McDermott DF, Sosman JA, Hodi FS, et al: Randomized phase II study of dacarbazine with or without sorafenib in patients with advanced melanoma. J Clin Oncol 25:474s, 2007 (suppl; abstr 8511)
20. Beasley GM, Tyler DS: Optimizing regional therapy for melanoma. Ann Surg Onc 16:1095-1097, 2009
21. Jonker DJ, Stewart R, Goel L, et al: A phase I study of the novel molecularly targeted vascular targeting agent, ExherinTM (ADH-1), shows activity in some patients with refractory solid tumors stratified according to N-cadherin expression. J Clin Oncol 23:204s, 2005 (suppl; abstr 3038)
22. Sessa C, Perotti A, Maur M, et al: An enriched phase I, pharmacokinetic and pharmacodynamic study of the N-cadherin (NCAD) cyclic competitive binder exherin (ADH-1) in patients with solid tumors. J Clin Oncol 24:131s, 2006 (suppl; abstract 3042)
23. Stewart DJ, Jonker DJ, Goel R, et al: Final clinical and pharmacokinetic (PK) results from a phase 1 study of the novel N-cadherin (N-cad) antagonist, Exherin (ADH-1), in patients with refractory solid tumors stratified according to N-cad expression. J Clin Oncol 24:124s, 2006 (suppl; abstract 3016)
24. Matsuyoshi N, Tanaka T, Toda K, et al: Identification of novel cadherins expressed in human melanoma cells. J Invest Dermatol 108:908-913, 1997 (Pubitemid 27272408)
25. Hsu MY, Meier FE, Nesbit M, et al: E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol 156:1515-1525, 2000 (Pubitemid 30646691)
26. Qi J, Chen N, Wang J, et al: Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the beta-catenin signaling pathway. Mol Biol Cell 16:4386-4397, 2005 (Pubitemid 41262905)
27. Augustine CK, Yoshimoto Y, Gupta M, et al: Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res 68:3777-3784, 2008
28. Toshimitsu H, Padussis JC, Turley R, et al: Targeting N-cadherin to augment the efficacy of regional chemotherapy: A potential double- edged sword? Ann Surg Oncol 17:S1, 2010 (abstr 28).
29. Beasley GM, McMahon N, Sanders G, et al: A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer 115:4766-4774, 2009
30. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001 (Pubitemid 32786276)
31. Sessa C, Perotti A, Maur M, et al: An enriched phase I, pharmacokinetic and pharmacodynamic study of the N-cadherin (NCAD) cyclic competitive binder exherin (ADH-1) in patients with solid tumors. J Clin Oncol 24:131s, 2006 (suppl; abstract 3042)
32. Ehrsson H, Eksborg S, Lindfors A: Quantitative determination of melphalan in plasma by liquid chromatography after derivatization with N-acetylcysteine. Chromatogr 380:222-228, 1986 (Pubitemid 16049885)
33. Yoshimoto Y, Augustine CK, Yoo JS, et al: Defining regional infusion treatment strategies for extremity melanoma: Comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. Mol Cancer Ther 6:1492-1500, 2007 (Pubitemid 46954016)
34. Bayesian Factor Regression Modeling (BFRM 2.0). http://www.stat.duke.edu/ research/software/west/bfrm
35. Eisen MB, Spellman PT, Brown PO, et al: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95:14863-14868, 1998
36. Augustine CK, Jung SH, Sohn I, et al: Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. Mol Cancer Ther 9:779-790, 2010
37. Adherex Technologies: ADH-1 Investigators Brochure, version 7.0. January 18, 2008
38. The Gene Ontology Consortium: Gene Ontology: Tool for the unification of biology. Nat Genet 25:25-29, 2000
39. Brady MS, Brown K, Patel A, et al: Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: Final report of a phase II clinical trial. Melanoma Res 19:106-111, 2009
40. McMahon N, Cheng TY, Beasley GM, et al: Optimizing melphalan pharmacokinetics in regional melanoma therapy: Does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol 16:953-961, 2009